Eugene D Shapiro1. 1. Department of Pediatrics, and Children's Clinical Research Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208064, New Haven, CT 06520-8064, USA. Eugene.Shapiro@Yale.edu
Abstract
BACKGROUND: Because case-control studies of the effectiveness of vaccines are nonexperimental, it is difficult to assure that bias does not affect the validity of the results. METHODS: A case-control study of the effectiveness of vaccines against Haemophilus influenzae type b (Hib) was replicated with a "sham" study. Cases were children > or =18 months of age with invasive infection caused by either Hib (original study) or Streptococcus pneumoniae (sham study) between January 1988 and December 1990. Controls were matched to the cases by both date and town of birth. RESULTS: Overall 34% of the 29 cases with invasive Hib infections and 64% of matched controls had received Hib vaccine. The effectiveness of Hib vaccines against infection with Hib was 88% (95% confidence interval, 57 to 97%; P < 0.01). In the sham study 74% of the 62 cases with invasive pneumococcal infections and 74% of matched controls had received Hib vaccine. The effectiveness of Hib vaccines against pneumococcal infection was 0% (P = 0.9). CONCLUSION: With the use of a virtually identical study design, vaccines against Hib were shown to be highly effective in preventing invasive Hib infections but were not effective in preventing invasive infections due to S. pneumoniae. Case-control studies are a valid method of assessing the effectiveness of vaccines.
BACKGROUND: Because case-control studies of the effectiveness of vaccines are nonexperimental, it is difficult to assure that bias does not affect the validity of the results. METHODS: A case-control study of the effectiveness of vaccines against Haemophilus influenzae type b (Hib) was replicated with a "sham" study. Cases were children > or =18 months of age with invasive infection caused by either Hib (original study) or Streptococcus pneumoniae (sham study) between January 1988 and December 1990. Controls were matched to the cases by both date and town of birth. RESULTS: Overall 34% of the 29 cases with invasive Hib infections and 64% of matched controls had received Hib vaccine. The effectiveness of Hib vaccines against infection with Hib was 88% (95% confidence interval, 57 to 97%; P < 0.01). In the sham study 74% of the 62 cases with invasive pneumococcal infections and 74% of matched controls had received Hib vaccine. The effectiveness of Hib vaccines against pneumococcal infection was 0% (P = 0.9). CONCLUSION: With the use of a virtually identical study design, vaccines against Hib were shown to be highly effective in preventing invasive Hib infections but were not effective in preventing invasive infections due to S. pneumoniae. Case-control studies are a valid method of assessing the effectiveness of vaccines.
Authors: Eugene D Shapiro; Marietta Vazquez; Daina Esposito; Nancy Holabird; Sharon P Steinberg; James Dziura; Philip S LaRussa; Anne A Gershon Journal: J Infect Dis Date: 2011-02-01 Impact factor: 5.226
Authors: Linda M Niccolai; Lorraine G Ogden; Catherine E Muehlenbein; James D Dziura; Marietta Vázquez; Eugene D Shapiro Journal: J Clin Epidemiol Date: 2007-06-07 Impact factor: 6.437
Authors: Molly F Franke; J Gregory Jerome; Wilfredo R Matias; Ralph Ternier; Isabelle J Hilaire; Jason B Harris; Louise C Ivers Journal: Vaccine Date: 2017-09-12 Impact factor: 3.641
Authors: Louise C Ivers; Isabelle J Hilaire; Jessica E Teng; Charles P Almazor; J Gregory Jerome; Ralph Ternier; Jacques Boncy; Josiane Buteau; Megan B Murray; Jason B Harris; Molly F Franke Journal: Lancet Glob Health Date: 2015-03 Impact factor: 26.763
Authors: Jill M Ferdinands; Manjusha Gaglani; Shekhar Ghamande; Emily T Martin; Donald Middleton; Arnold S Monto; Fernanda Silveira; Helen K Talbot; Richard Zimmerman; Emily R Smith; Manish Patel Journal: J Infect Dis Date: 2021-07-02 Impact factor: 5.226